NXTC

NextCure  Inc

NXTC, USA

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

https://www.nextcure.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NXTC
stock
NXTC

NextCure files for offering of up to 2.52 million shares of common stock by selling stockholders - SEC filing marketscreener.com

Read more →
NXTC
stock
NXTC

Piper Sandler Keeps Their Buy Rating on NextCure (NXTC) The Globe and Mail

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$17.6667

Analyst Picks

Strong Buy

0

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.29

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-36.47 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-21.77 %

Low 2%

High 10%

Debt to Equity

-

Medium

0.68

Low 1

High 0.3

Investors

* Institutions hold a combined 42.30% of the total shares of NextCure  Inc

1.

Sofinnova Ventures

(8.3201%)

since

2025/03/31

2.

Affinity Asset Advisors, LLC

(7.1702%)

since

2025/03/31

3.

Pfizer Inc

(5.8909%)

since

2025/03/31

4.

Citigroup Inc

(4.4199%)

since

2025/03/31

5.

Vanguard Group Inc

(3.0745%)

since

2025/03/31

6.

Cable Car Capital LLC

(2.0867%)

since

2025/03/31

7.

Vanguard Total Stock Mkt Idx Inv

(1.8706%)

since

2025/07/31

8.

BlackRock Inc

(1.7335%)

since

2025/03/31

9.

Renaissance Technologies Corp

(1.4946%)

since

2025/03/31

10.

CARDIFF PARK ADVISORS, LLC

(0.8159%)

since

2025/03/31

11.

Geode Capital Management, LLC

(0.7355%)

since

2025/03/31

12.

Macquarie Group Ltd

(0.4671%)

since

2025/03/31

13.

Macquarie Healthcare I

(0.4671%)

since

2025/07/31

14.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4321%)

since

2025/07/31

15.

Sio Capital Management, LLC

(0.4048%)

since

2025/03/31

16.

Fidelity Extended Market Index

(0.3843%)

since

2025/07/31

17.

ADAR1 Capital Management LLC

(0.3737%)

since

2025/03/31

18.

Armistice Capital, LLC

(0.3239%)

since

2025/03/31

19.

Citadel Advisors Llc

(0.2823%)

since

2025/03/31

20.

Barclays PLC

(0.2102%)

since

2025/03/31

21.

State Street Corp

(0.2036%)

since

2025/03/31

22.

Vanguard Explorer Inv

(0.1751%)

since

2025/06/30

23.

Northern Trust Corp

(0.1479%)

since

2025/03/31

24.

IEQ CAPITAL, LLC

(0.1163%)

since

2025/03/31

25.

Fidelity Series Total Market Index

(0.0953%)

since

2025/07/31

26.

Spartan Extended Market Index Pool F

(0.0943%)

since

2025/07/31

27.

NT Ext Equity Mkt Idx Fd - L

(0.0857%)

since

2025/06/30

28.

Northern Trust Extended Eq Market Idx

(0.0857%)

since

2025/06/30

29.

Extended Equity Market Fund K

(0.0788%)

since

2025/06/30

30.

Schonfeld Strategic Advisors LLC

(0.059%)

since

2025/03/31

31.

NT Ext Equity Mkt Idx Fd - NL

(0.0453%)

since

2025/06/30

32.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0352%)

since

2025/06/30

33.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0242%)

since

2025/06/30

34.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0204%)

since

2024/12/31

35.

U.S. Equity Market Fund F

(0.0167%)

since

2025/06/30

36.

NT Quality Small Cap Core

(0.0129%)

since

2025/06/30

37.

NT Quality SCC US Fund - L

(0.0129%)

since

2025/06/30

38.

BNYM Mellon SL Market Completion UC1

(0.0127%)

since

2025/06/30

39.

Extended Equity Market Fund M

(0.0099%)

since

2025/06/30

40.

Diversified Equity Fund F

(0.0079%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-3.22

EPS Estimate

-0.45

EPS Difference

-2.77

Surprise Percent

-615.5556%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.